Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Giampiero Girolomoni, Robert Strohal, L. Puig, et al.
Journal of the European Academy of Dermatology and Venereology (2017) Vol. 31, Iss. 10, pp. 1616-1626
Open Access | Times Cited: 231

Showing 1-25 of 231 citing articles:

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt, Andrea Chiricozzi
Clinical Reviews in Allergy & Immunology (2018) Vol. 55, Iss. 3, pp. 379-390
Open Access | Times Cited: 590
The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis
Cristina Albanesi, Stefania Madonna, Paolo Gisondi, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 348
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, et al.
The Lancet (2020) Vol. 395, Iss. 10230, pp. 1115-1125
Open Access | Times Cited: 261
Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Wolf‐­Henning Boehncke
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 254
Current Developments in the Immunology of Psoriasis.
Franziska Grän, Andreas Kerstan, Edgar Serfling, et al.
The Yale Journal of Biology and Medicine (2020) Vol. 93, Iss. 1, pp. 97-110
Closed Access | Times Cited: 173
Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders
Michael P. Schön
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 160
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Kevin Yang, Allen S. W. Oak, Boni E. Elewski
American Journal of Clinical Dermatology (2020) Vol. 22, Iss. 2, pp. 173-192
Open Access | Times Cited: 144
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Jashin J. Wu, Arthur Kavanaugh, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 6, pp. 797-806
Open Access | Times Cited: 109
IL-25 (IL-17E) in epithelial immunology and pathophysiology
Julia Borowczyk, Maria S. Shutova, Nicolò Costantino Brembilla, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 1, pp. 40-52
Open Access | Times Cited: 108
Cutaneous Malassezia: Commensal, Pathogen, or Protector?
Shree Harsha Vijaya Chandra, Srinivas Ramasamy, Thomas L. Dawson, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 10
Open Access | Times Cited: 107
Current Concepts of Psoriasis Immunopathogenesis
Marijana Vičić, Marija Kaštelan, Ines Brajac, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11574-11574
Open Access | Times Cited: 105
Gut Microbiota in Psoriasis
Mihaela Cristina Buhaș, Laura Ioana Gavrilaș, Rareș Candrea, et al.
Nutrients (2022) Vol. 14, Iss. 14, pp. 2970-2970
Open Access | Times Cited: 73
Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
Nicolò Costantino Brembilla, Wolf‐­Henning Boehncke
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 43
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
L. Sawyer, K Malottki, Celia Sabry-Grant, et al.
PLoS ONE (2019) Vol. 14, Iss. 8, pp. e0220868-e0220868
Open Access | Times Cited: 137
Advances in Understanding the Immunological Pathways in Psoriasis
Simona Roxana Georgescu, Mircea Tampa, Constantin Căruntu, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 739-739
Open Access | Times Cited: 132
Models in the Research Process of Psoriasis
Katarzyna Bocheńska, Elwira Smolińska, Marta Moskot, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 12, pp. 2514-2514
Open Access | Times Cited: 116
The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
Stefania Madonna, Giampiero Girolomoni, Charles A. Dinarello, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3318-3318
Open Access | Times Cited: 115
Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities
Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 113
Dendritic cells: The driver of psoriasis
Ao Wang, Yanping Bai
The Journal of Dermatology (2019) Vol. 47, Iss. 2, pp. 104-113
Closed Access | Times Cited: 112
Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups
Bridget Kaufman, Andrew Alexis
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 405-423
Closed Access | Times Cited: 109
Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis
Yu Ri Woo, Dae Cho, Hyun Park
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 12, pp. 2684-2684
Open Access | Times Cited: 104
Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
Robert G. Petit, Amanda Cano, A. Ortiz, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4983-4983
Open Access | Times Cited: 84
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial
Mamitaro Ohtsuki, Hideki Fujita, Masao Watanabe, et al.
The Journal of Dermatology (2019) Vol. 46, Iss. 8, pp. 686-694
Open Access | Times Cited: 77
The biological basis of disease recurrence in psoriasis: a historical perspective and current models
L. Puig, Antonio Costanzo, Ernesto J. Muñoz‐Elías, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 5, pp. 773-781
Open Access | Times Cited: 60
Deucravacitinib for the Treatment of Psoriatic Disease
Ana Maria Lé, L. Puig, Tiago Torres
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 6, pp. 813-822
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top